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Background
Appropriateness of care is defined as the adequacy of any care to meet patient needs, in accordance with practice guidelines [1] ; inappropriate care includes misuse, underuse and overuse [2] [3] [4] . Chassin et al. reported that the frequency of underuse varies between 40% and 60% of all provided care [2] , whereas Morgan et al. reported that the frequency of overuse varies between 10% and 30% [4] . Improving appropriateness of care is a priority in Europe, including France [5] , especially because of its potential impact on quality of care.
Drug use holds a special place within appropriateness of care. The impact of drug adverse events is important; in France, they have been implicated in 20% of emergency room visits and 3-5% of hospitalizations [6, 7] . Recent epidemiological studies indicate that 30-50% of serious adverse events related to drugs could be avoided [8, 9] , which means that their frequency, severity and impact could be reduced by appropriate care and organization. Improvement of the appropriateness of drug prescriptions could significantly reduce adverse events in outpatients and hospitalized patients; adverse events related to drugs may occur in 17% of hospitalized patients [10] . Furthermore, studies have reported that 20-60% of drug prescriptions may be inappropriate [11, 12] .
Oral anticoagulants (Vitamin K Antagonists [VKAs] and non-vitamin K antagonist oral anticoagulants [NOACs] ) are among the drugs most frequently involved in adverse events [13] . Epidemiological studies report that bleeding events related to VKAs are among the most frequent drug adverse events [6, 8, 9] . In France, VKAs may be involved in 17,000 hospitalisations per year, more than half of which could be avoided [14] . VKAs are especially difficult to use because of the narrow therapeutic index and the need for regular laboratory monitoring based on the international normalized ratio.
The development of appropriateness indicators for oral anticoagulation prescriptions is also justified by the recent arrival of NOACs, which share the same bleeding risk as VKAs. Furthermore, the appropriateness of oral anticoagulant prescriptions is a major public health issue because of the large targeted population and frequency of use [15] . Cardiologists, who often prescribe such oral anticoagulants, are significantly concerned by this issue, as are other clinicians with whom they may share patient management responsibilities in hospital (especially neurologists, geriatricians, emergency physicians and anesthesiologists).
Identified inappropriate oral anticoagulant prescription practices in hospital may explain some bleeding or thrombotic complications [16] [17] [18] ; such adverse events could be reduced by improving prescriptions and monitoring practices [19] . Thus, the large targeted population and the strong risk of adverse events justify the importance of developing tools to improve the appropriateness of oral anticoagulant prescriptions in hospitalized patients, especially in cardiology.
Feedback of indicators of the appropriateness of oral anticoagulant prescriptions to health professionals could strengthen tools for quality improvement and selfevaluation in hospital [20] . The existence of clear guidelines for oral anticoagulant prescription in clinical practice [14, 15, [21] [22] [23] [24] [25] [26] [27] would allow the development of such indi-cators to detect inappropriate prescriptions. Furthermore, as there is a need to provide regular feedback of indicators to health professionals to improve practices [28] , such indicators could be better used if automated from the hospital information system.
There is currently a lack of indicators to measure the appropriateness of oral anticoagulant prescriptions for validated clinical indications (atrial fibrillation, valvular heart disease and a prosthetic heart valve, venous thromboembolic disease) or clinical situations in patients under oral anticoagulants (trauma or planned surgery); such indicators could provide regular monitoring of oral anticoagulant prescriptions for these clinical situations. Published studies have mainly focused on the development of indicators in atrial fibrillation [29] , especially the indication for warfarin therapy [30] [31] [32] [33] [34] [35] .
Beyond the existence of practice guidelines, which are excellent sources from which potential indicators can be identified, it is necessary to demonstrate the utility of indicators before operational implementation, to maximize the therapeutic efficacy of oral anticoagulants while minimizing adverse events [29] . Thus, the challenge is to provide useful and operational tools that can be implemented in any healthcare institution to help clinicians to improve their practice.
We aimed to define a panel of useful and implementable indicators of the appropriateness of oral anticoagulant prescriptions in hospitalized patients that would cover the main clinical situations in which oral anticoagulants are prescribed, automated from the hospital information system, and that could be used by cardiologists and other clinicians interested in strengthening tools for quality improvement and self-evaluation in hospital.
Methods

Context
This work was performed during the first step of the PACHA study (Pertinence des prescriptions d'AntiCoagulants oraux à l'Hôpital Automatisés), which focuses on the development and validation of indicators of the appropriateness of oral anticoagulant prescriptions in adult medicine automated from the information system of Bordeaux University Hospital and Georges-Pompidou European Hospital.
The PACHA study protocol was approved by institutional review boards and ethics committees (Clinical Trial Registration: NCT02898090). The steering and scientific committees of the PACHA study included cardiologists, neurologists, geriatricians, emergency physicians, anesthesiologists, specialists in biology or hematology, epidemiologists, hospital information system specialists, pharmacologists, pharmacists and statisticians.
Literature review
Bibliographic search
A systematic literature review was conducted by the steering and scientific committees to identify guidelines related to targeted clinical situations for which a prescription of oral anticoagulants (VKAs or NOACs) is indicated or not, and their conditions of appropriateness. The review was based on a systematic comprehensive search in MEDLINE, SCOPUS and a French public health database (Banque de Données en Santé Publique) ( Supplementary Fig. 1 ), to identify European clinical practice guidelines and European expert consensus recommendations for the appropriate use of a VKA or a NOAC in general or targeted clinical situations (atrial fibrillation, valvular heart disease and a prosthetic heart valve, venous thromboembolic disease, trauma or planned surgery in patients under oral anticoagulants), published in English or French between 1st January 2005 and 30th June 2015. This review also aimed to identify reports from the French High Authority for Health (Haute Autorité de Santé) related to the use of VKAs and NOACs. We checked lists of references to identify other relevant articles, and references were excluded if only the abstract was available.
Selection of guidelines and expert recommendations
References were first screened by titles and abstracts by members of the steering committee (A. P.-M., F. S.-G. and L.-R. S.). Abstracts were retained for full review when they met the inclusion criteria or when more information was required to ascertain eligibility. Two other steering committee members who specialized in medical pharmacology (D. B. and P. N.) were asked to ensure the relevance and completeness of the selected articles.
Critical appraisal and classification by level of evidence
We extracted information from the selected articles using a standardized grid to describe their level of evidence and strength of recommendations as reported in references. We also described the main elements for judging their methodological quality according to reference methodological guides from the French High Authority for Health [36] [37] [38] : names and qualifications of members who participated in their development; declaration of conflicts of interest; sources of funding and influence on the recommendations; objectives and rationale for the study; conduct of a systematized literature review (detailed search strategy specifying keywords, sources and criteria for inclusion of studies); conduct of a critical appraisal (strengths and limits, levels of evidence); list of the selected publications; and proposal of graded recommendations. The identified guidelines or recommendations were thus classified into three levels: ''good'' when the development process was reported explicitly and used a formal method consistent with good practices; ''insufficient to moderate'' when the development process was not reported explicitly or did not use a formal method; or ''undefined'' when the development process was not reported. objective; numerator and denominator; inclusion and exclusion criteria; and data sources. According to guidelines, we defined their conditions of appropriateness in terms of drug dosage, duration of treatment, pretreatment assessment, compliance with contraindications and monitoring during treatment. The selected indicators could refer to misuse, underuse or overuse, as defined in the literature [2] [3] [4] .
Definition and pre-selection of indicators
All members of the PACHA steering and scientific committees prioritized indicators based upon their utility (defined as the indicator ability to detect inappropriate oral anticoagulant prescriptions and to implement improvement actions), their operational implementation in terms of frequency or severity (defined as the indicator ability to detect frequent or severe inappropriate oral anticoagulant prescriptions allowing practice improvement) and their operational feasibility for implementation from the hospital information system (defined as the availability of data within the hospital information system for measuring the indicator). This pre-selection was performed considering the characteristics of each indicator (definition, domain [bleeding risk, thrombotic risk, or adverse effect], prescription category [indication, initiation, dosage, duration of treatment, monitoring or relay] and type of oral anticoagulant [VKA, NOAC or both]), and the characteristics of guidelines from which the indicators were identified (method of development, quality of the method and level of evidence).
Consensus
Following guidelines [40] , we set up a two-round Delphi consensus process, completed by a synthesis meeting, to select a panel of useful and implementable indicators. During each round, the experts were asked to rate the indicator ability to detect inappropriate oral anticoagulant prescriptions and to implement corrective actions (utility: yes or no), and to detect sufficiently frequent or severe inappropriate oral anticoagulant prescriptions to improve practices (operational implementation in terms of frequency or severity: yes or no). The experts were not asked to rate the feasibility of implementation of indicators from the hospital information system.
The steering committee had previously defined that an indicator would be selected if at least eight out of 10 experts considered the indicator to be both useful and implementable (strong consensus for selection). We also defined that an indicator would be deleted if at least eight out of 10 experts considered the indicator to be not useful and not implementable (strong consensus for deletion). All expert judgments were reported in an anonymized database.
Selection of experts
We selected forty French-speaking European experts from France, Belgium or Switzerland; they were specialized in cardiology, vascular medicine, neurology, geriatrics, emergency medicine, anesthesiology, pharmacology or hematology. The expert selection was based upon clinical expertise in the targeted clinical situations or prescriptions of oral anticoagulants; the scientific committee referred to professional networks and lists of authors involved in the development of European clinical practice guidelines or recommendations.
Delphi process
During the first round, the experts were asked to rate the utility and operational implementation in terms of frequency and severity (as defined above) of the proposed indicators on a qualitative binary scale (yes or no). The experts were also asked to give their opinion on the way the proposed indicators were defined and formulated, especially for those definitions or criteria that were not consensual in the literature. Each expert also had the opportunity to propose up to three new clearly defined indicators, while specifying the guidelines or recommendations from which they were identified.
During the second round, we sent an E-mail to all the experts, reporting the main results of the first round. For the indicators that had not achieved strong consensus, the experts were asked to confirm or modify their judgment. As well as during the first round, E-mails were sent to experts weekly for 1 month to limit non-responders.
Final synthesis meeting
A final synthesis meeting was organized within the steering committee to validate the final list of selected indicators that had obtained a strong consensus; some reformulations were considered according to experts' recommendations. We then established the order in which the final panel of indicators would be operationally implemented from the hospital information system. Final feedback was sent to the experts involved in the Delphi consensus process.
Results
Literature review
We identified 38 references from titles and abstracts (Supplementary Table 2 ). After complete reading of all references, 32 were selected. These references were mostly from European high authorities for health and learned societies.
Definition and pre-selection of indicators
We identified 84 indicators of the appropriateness of oral anticoagulant prescriptions ( Fig. 1 ). Nineteen indicators were then short-listed by the scientific committee (Table 1) , considering their operational feasibility for implementation from the hospital information system, and submitted to the Delphi process.
The 19 pre-selected indicators concerned VKA or NOAC prescriptions, and all their potential domains of utility (bleeding risk, thrombotic risk or adverse event); they related to all the prescription categories previously defined, among indication, initiation, dosage or monitoring of oral anticoagulants, but no indicator concerned duration of treatment or relay. The majority of the 19 indicators were identified from clinical practice guidelines with a quality of method that had been judged as good or moderate; four indicators were based upon guidelines from the French High Authority for Health ( Supplementary Table 3 ). 
Consensus
Panel of experts
Twenty-two of the 40 contacted experts (55%) agreed to participate; all 22 (100%) participated in both rounds. Participants were from varied fields of expertise, and most (82%) practiced in France. All the experts practiced in healthcare institutions: 91% practiced in university healthcare institutions; and 55% practiced as senior university professors ( Table 2 ). Of the 18 experts who did not participate in the Delphi process, half practiced in France, five (28%) practiced in Belgium and four (22%) practiced in Switzerland; all were senior professors. Experts who did not wish to participate often justified their refusal in terms of lack of expertise.
Delphi process and final synthesis meeting
During the Delphi process, sixteen indicators obtained a strong consensus for selection (Table 3 ). Three indicators did not achieve expert consensus, although at least 50% of the experts judged them as both useful and operational (Supplementary Table 4 ).
No additional indicator was selected by the steering committee among those proposed by the experts. Some had already been identified, but not previously selected, because of a lack of utility or operational feasibility (n = 5 indicators) or concerned a reformulation of one of the 19 pre-selected indicators (n = 6 indicators) or did not relate to the study's targeted clinical situations (n = 1 indicator). Compliance with the VKA initial dosage for patients in treatment initiation: fluindione 20 mg/day, to decrease to 10 mg/day in patients aged ≥ 75 years; warfarin 6 or 7 mg/day, to decrease to 4 mg/day in patients aged ≥ 75 years 8
Compliance with the HAS-BLED bleeding risk evaluation before VKA treatment initiation for atrial fibrillation 9
Patients with a NOAC prescription despite valvular atrial fibrillation 10
Absence of compliance with a VKA or NOAC prescription in patients aged < 75 years with atrial fibrillation and a CHA 2 DS 2 -VASc score ≥ 2 despite validated clinical indication 11
Absence of compliance with a VKA or NOAC prescription in patients with atrial fibrillation and a CHA 2 DS 2 -VASc score ≥ 2 (or ≥ 1 in men) despite validated clinical indication to prevent thromboembolic events 12
Compliance with NOAC dosage adaptation related to bleeding risk in patients treated for non-valvular atrial fibrillation: dabigatran 110 mg twice a day (instead of 150 mg twice a day) in patients aged ≥ 80 years or receiving concomitant treatment with verapamil or with severe bleeding risk (HAS-BLED score ≥ 3) or moderate renal failure (creatinine clearance 30-49 mL/min); rivaroxaban 15 mg/day (instead of 20 mg/day) in patients with severe bleeding risk (HAS-BLED score ≥ 3) or moderate renal failure (creatinine clearance 30-49 mL/min) 13 Compliance with monitoring during the treatment process in patients under a VKA for atrial fibrillation: arterial hypertension, INR, concomitant treatment with a haemostatic agent (especially acetylsalicylic acid or non-steroidal anti-inflammatory drug), excessive alcohol consumption 14
Patients with a mechanical prosthetic heart valve without a VKA prescription despite validated clinical indication 15 Patients under a NOAC despite a mechanical prosthetic heart valve 16 Compliance with the VKA or NOAC initial dosage for patients with pulmonary embolism: warfarin initial dosage equal to 10 mg/day (patients aged < 60 years) or 5 mg/day (patients aged ≥ 60 years or hospitalized); rivaroxaban 15 mg twice a day for 3 weeks and then 20 mg/day; apixaban 10 mg twice a day for 7 days and then 5 mg twice a day; dabigatran 150 mg twice a day (or 110 mg twice a day if aged ≥ 80 years or receiving concomitant treatment with verapamil) 17 Compliance with the cerebral scanner in an emergency in patients under a VKA with severe cranial trauma (consciousness disorder, amnesia, altered Glasgow score) 18 Compliance with VKA treatment discontinuation and emergency INR control in patients with cranial trauma or any other trauma with a severe bleeding risk 19 Compliance with the cerebral scanner in the first hour after arrival at the emergency unit in patients under an OA with mild cranial trauma The steering committee approved and ordered the 16 indicators that obtained a strong consensus, while validating the final definition of these indicators (Table 4 ). Six indicators were reformulated considering the experts' proposals (Supplementary Table 5 ).
Characteristics of the final panel of selected indicators
The final panel of selected indicators aims to evaluate practices in adult medicine, and includes three indicators that also consider geriatric specificities. Two-thirds of the 16 indicators focus on the appropriateness of oral anticoagulant prescriptions in general or in patients with atrial fibrillation; the other third focus on the appropriateness of prescriptions in patients with a prosthetic heart valve, venous thromboembolism or trauma under oral anticoagulants (Table 4 ). Twelve indicators (75%) aim to alert about the existence of inappropriate prescriptions, and four indicators (25%) aim to alert about the existence of underuse or overuse. Thirteen indicators (81%) focus on bleeding risk, six indicators (38%) focus on the risk of adverse events and five indicators (31%) focus on thrombotic risk; seven indicators measure several risks simultaneously. These indicators concern all the prescription categories previously defined, among indication, initiation, and dosage or monitoring of oral anticoagulants. Finally, seven indicators (44%) relate to VKA or NOAC prescriptions considered simultaneously, whereas six indicators (38%) relate to VKAs only, and three indicators (18%) relate to NOACs only. All these selected indicators are formulated as proportions, the numerators and denominators of which are presented in Table 5 .
Discussion
We conducted a literature review that allowed a shortlist of 19 indicators of the appropriateness of oral anticoagulant prescriptions to be submitted to expert judgment. During the consensus, 16 indicators were judged both useful and implementable. This final panel of 16 selected indicators covered all the targeted clinical situations, with the exception of planned surgery.
One of the strengths of the study is the development of a panel of indicators based upon a comprehensive review from European high authorities for health and learned societies. The panel was also based on a critical appraisal of the literature to assess the quality of guideline implementation, while collecting levels of evidence and strengths of recommendations. Despite the great diversity of reported classifications for levels of evidence and strengths of recommendations (the French High Authority for Health classification, the National Institute for Health and Care Excellence classification, the European Society of Cardiology classification or the GRADE classification), most of the 19 pre-selected indicators were identified from clinical practice guidelines, whose quality had been considered as good according to reference methodological guides [41] [42] [43] [44] [45] [46] [47] , or from recommendations from the French high authorities for health [14, 15] .
Another strength of the study was the use of a Delphi consensus to select a panel of useful and implementable indicators. A first pre-selection of the indicators by the study committee was necessary because of the high number of indicators identified (n = 84). The 19 pre-selected indicators were then submitted to the judgment of European experts whose guidelines for targeted clinical situations are similar to French guidelines. While expecting a generalization of these indicators beyond the French territory, the mobilization of a European research group on these important issues allowed us to collect opinions on the pre-selected indicators, especially for some definitions or criteria that were not consensual in the literature, to consider other potential indicators and guidelines that could have been failed and to achieve consensus on a reduced number of indicators.
Even if the expressed judgments depend on the constitution of the expert group, the strength of this consensus is that it is based on opinions from experts who practice in various clinical or non-clinical fields of expertise covering the targeted clinical situations. The distribution of experts was balanced within these different fields of expertise, which tended to improve the representativeness of expressed opinions.
All experts participated in both rounds, demonstrating great interest in the development of indicators of the appropriateness of oral anticoagulant prescriptions. This panel of experts constituted mostly experts practicing in France; however, the majority had previously participated in the development of European recommendations that were among those identified in our literature review. The decision to favour experts practicing in university hospital healthcare institutions was justified by the need to question a panel of experts with a good knowledge of European recommendations and their methods of elaboration.
During the Delphi process, we paid great attention to the opinions of experts regarding the way that the proposed indicators were defined and formulated; this constituted a solid basis on which the steering committee relied to define more precisely the indicators that would later be implemented from the hospital information system. We selected only indicators that obtained a strong consensus for both utility and implementation. Nevertheless, a strong consensus was obtained for the selection of 16 indicators; only three indicators did not achieve consensus. This highlights the quality of the pre-selection phase, which allowed selection of a [16] [17] [18] . Analysis of the characteristics of this final panel of selected indicators shows that a third relate to the appropriateness of oral anticoagulant prescriptions for patients with atrial fibrillation, which seems justified by the fact that it is one of the most frequent validated clinical indications for oral anticoagulants [42] ; contrary to published studies [30] [31] [32] [33] [34] [35] , these indicators concern indication, drug dosage or monitoring of all oral anticoagulants (VKAs or NOACs). Only one indicator relating to the appropriateness of oral anticoagulant prescriptions for the treatment of venous thromboembolism was submitted to the judgment of experts and was selected, despite the high frequency of such events [46, 48] ; this is explained by the fact that most indicators of this clinical situation concerned compliance with treatment duration or relay towards injectable anticoagulants, for which there is a lack of data traceability within the hospital information system. Two indicators relate to the appropriateness of oral anticoagulant prescriptions in patients with a prosthetic heart valve; such indicators will be useful to help cardiologists to prevent severe thrombotic or bleeding risk. Two other indicators focus on care management of patients with trauma under oral anticoagulants; such indicators may be used by clinicians in an emergency context requiring the adaptation and monitoring of oral anticoagulants previously prescribed for cardiovascular diseases. As such, this panel of indicators covered all the targeted clinical situations, with the exception of planned surgery; such indicators were not selected because they referred to preoperative relay toward injectable anticoagulants or preoperative monitoring of oral anticoagulants, for which data traceability within the hospital information system was also lacking, especially in ambulatory surgery. Finally, three-quarters of the selected indicators are designed to alert about the existence of inappropriate prescriptions, as well as bleeding or adverse event risk. As the three indicators that did not achieve consensus were also concerned with these characteristics, the lack of consensus for their selection appears to be really because of a lack of utility or operational implementation in accordance with the objective of the Delphi process. Thus, the analysis of this panel of indicators highlights the importance of the feasibility assessment, for both their selection and implementation from the hospital information system, to strengthen their use by clinicians and their potential for generalization.
Conclusions
This study addresses the current lack of quality indicators of the appropriateness of oral anticoagulant prescriptions, based upon guidelines and validated clinical indications. By considering the utility, operational implementation in terms of frequency or severity and feasibility of the indicators, we have strengthened their potential for generalization for European implementation in healthcare institutions through a structured approach to improve the quality of oral anticoagulant prescriptions. Such transferability between different contexts and countries is important to improve the effectiveness of quality-of-care strategies based upon the use of indicators [49] . As such, this panel of indicators can already be used by clinicians, especially cardiologists, who practice in European healthcare institutions in which data are available and are interested in delivering regular feedback to health professionals.
We will coordinate the operational implementation of these indicators from the hospital information system of Bordeaux University Hospital and Georges-Pompidou European Hospital, to assess their metrological properties to detect inappropriate prescriptions. The more accurate indicators will be fed back to prescribing health professionals.
As part of a comprehensive approach to quality-of-care improvement, taking into account the entire health care system [50] , implementation of these indicators will provide a framework in which quality of care can be measured and improved.
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